BRPI0711625A2 - derivados de arilaminopiridina substituìda por heteroarila como inibidores de mek - Google Patents

derivados de arilaminopiridina substituìda por heteroarila como inibidores de mek Download PDF

Info

Publication number
BRPI0711625A2
BRPI0711625A2 BRPI0711625-0A BRPI0711625A BRPI0711625A2 BR PI0711625 A2 BRPI0711625 A2 BR PI0711625A2 BR PI0711625 A BRPI0711625 A BR PI0711625A BR PI0711625 A2 BRPI0711625 A2 BR PI0711625A2
Authority
BR
Brazil
Prior art keywords
alkyl
formula
substituted
hydrogen
unsubstituted
Prior art date
Application number
BRPI0711625-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Andreas Goutopoulos
Benny C Askew
Xiaoling Chen
Srinivasa Karra
Henry Yuen Sen Chung
Original Assignee
Serono Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serono Lab filed Critical Serono Lab
Publication of BRPI0711625A2 publication Critical patent/BRPI0711625A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0711625-0A 2006-04-19 2007-04-18 derivados de arilaminopiridina substituìda por heteroarila como inibidores de mek BRPI0711625A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79307306P 2006-04-19 2006-04-19
US60/793,073 2006-04-19
PCT/US2007/009456 WO2007123936A1 (en) 2006-04-19 2007-04-18 Novel heteroaryl-substituted arylaminopyridine derivatives as mek inhibitors

Publications (1)

Publication Number Publication Date
BRPI0711625A2 true BRPI0711625A2 (pt) 2011-12-06

Family

ID=38357968

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0711625-0A BRPI0711625A2 (pt) 2006-04-19 2007-04-18 derivados de arilaminopiridina substituìda por heteroarila como inibidores de mek

Country Status (14)

Country Link
US (1) US8076486B2 (enExample)
EP (1) EP2013180A1 (enExample)
JP (1) JP5525812B2 (enExample)
KR (1) KR20090005195A (enExample)
CN (2) CN101426766B (enExample)
AR (1) AR060807A1 (enExample)
AU (1) AU2007240860A1 (enExample)
BR (1) BRPI0711625A2 (enExample)
CA (1) CA2644425A1 (enExample)
EA (1) EA200802050A1 (enExample)
IL (1) IL194546A0 (enExample)
MX (1) MX2008013308A (enExample)
WO (1) WO2007123936A1 (enExample)
ZA (1) ZA200807263B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007123939A2 (en) * 2006-04-19 2007-11-01 Laboratoires Serono S.A. Novel arylamino n-heteraryls as mek inhibitors
EP2231636B1 (en) * 2007-12-07 2011-09-14 Novartis AG Pyrazole derivatives and use thereof as inhibitors of cyclin dependent kinases
US9084781B2 (en) 2008-12-10 2015-07-21 Novartis Ag MEK mutations conferring resistance to MEK inhibitors
WO2011106298A1 (en) 2010-02-25 2011-09-01 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
BR112012022801B8 (pt) 2010-03-09 2019-10-29 Dana Farber Cancer Inst Inc método de identificar um indivíduo que tem câncer que é provável beneficiar-se do tratamento com uma terapia de combinação com um inibidor de raf e um segundo inibidor e uso de um inibidor de raf e um segundo inibidor para a fabricação de um medicamento para tratar câncer
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
US20150141470A1 (en) 2012-05-08 2015-05-21 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
WO2014007228A1 (ja) 2012-07-03 2014-01-09 小野薬品工業株式会社 ソマトスタチン受容体作動活性を有する化合物およびその医薬用途
KR20170125931A (ko) * 2015-03-10 2017-11-15 오리진 디스커버리 테크놀로지스 리미티드 면역조절제로서의 3-치환된 1,3,4-옥사다이아졸 및 티아다이아졸 화합물
TN2017000483A1 (en) 2015-05-20 2019-04-12 Amgen Inc Triazole agonists of the apj receptor.
WO2017033113A1 (en) 2015-08-21 2017-03-02 Acerta Pharma B.V. Therapeutic combinations of a mek inhibitor and a btk inhibitor
US10150754B2 (en) * 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
WO2017192485A1 (en) 2016-05-03 2017-11-09 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
WO2018097945A1 (en) 2016-11-16 2018-05-31 Amgen Inc. Heteroaryl-substituted triazoles as apj receptor agonists
US10906890B2 (en) 2016-11-16 2021-02-02 Amgen Inc. Triazole phenyl compounds as agonists of the APJ receptor
WO2018093580A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Triazole pyridyl compounds as agonists of the apj receptor
EP3541792B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
MA46827A (fr) 2016-11-16 2019-09-25 Amgen Inc Composés de triazole à substitution cycloalkyle en tant qu'agonistes du récepteur apj
US11191762B2 (en) 2016-11-16 2021-12-07 Amgen Inc. Alkyl substituted triazole compounds as agonists of the APJ Receptor
WO2018204532A1 (en) 2017-05-03 2018-11-08 Vivace Therapeutics, Inc. Non-fused tricyclic compounds
JP7245229B2 (ja) 2017-08-21 2023-03-23 ビバーチェ セラピューティクス，インク． ベンゾスルホニル化合物
WO2019089335A1 (en) 2017-11-03 2019-05-09 Amgen Inc. Fused triazole agonists of the apj receptor
EP3720430A4 (en) 2017-12-06 2021-05-05 Vivace Therapeutics, Inc. BENZOCARBONYL COMPOUNDS
BR112020011162A2 (pt) * 2017-12-07 2020-11-17 Amplyx Pharmaceuticals, Inc. agentes antifúngicos derivados de piridina substituída por heterociclo
CN110317190A (zh) * 2018-03-28 2019-10-11 首都医科大学 一种三唑-羧酸酯类衍生物在医药领域的应用
WO2019213006A1 (en) 2018-05-01 2019-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the apj receptor
EP3793551A4 (en) 2018-05-16 2022-01-26 Vivace Therapeutics, Inc. OXADIAZOLE COMPOUNDS
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
EP4061364A4 (en) * 2019-11-20 2023-09-13 Vivace Therapeutics, Inc. HETEROARYL COMPOUNDS
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
JP2024521788A (ja) 2021-05-27 2024-06-04 ミラティ セラピューティクス， インコーポレイテッド 併用療法
WO2025054260A1 (en) * 2023-09-07 2025-03-13 Kinnate Biopharma Inc. Inhibitors of mek kinase
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL144215A0 (en) 1999-01-13 2002-05-23 Warner Lambert Co 1-heterocycle substituted diarylamines
GB2373245A (en) * 2001-03-12 2002-09-18 Bayer Ag Pyridinyl pyrazoles and their use for the treatment of COPD
CA2498281A1 (en) * 2002-09-10 2004-03-25 Pharmacia Italia S.P.A. Substituted pyridine derivatives as antitumor agent
AU2003293376A1 (en) * 2002-12-10 2004-06-30 Imclone Systems Incorporated Anti-angiogenic compounds and their use in cancer treatment
US20050004186A1 (en) 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
AU2004229392A1 (en) * 2003-04-09 2004-10-28 Exelixis, Inc. Tie-2 modulators and methods of use
WO2005000818A1 (en) 2003-06-27 2005-01-06 Warner-Lambert Company Llc 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors
WO2005004818A2 (en) * 2003-07-09 2005-01-20 Imclone Systems Incorporated Heterocyclic compounds and their use as anticancer agents
JP4768628B2 (ja) 2003-11-19 2011-09-07 アレイ バイオファーマ、インコーポレイテッド Ｍｅｋの二環系阻害剤及びその使用方法
PT1802579E (pt) * 2004-10-20 2014-02-17 Merck Serono Sa Derivados da 3-arilaminopiridina

Also Published As

Publication number Publication date
EP2013180A1 (en) 2009-01-14
MX2008013308A (es) 2008-10-27
ZA200807263B (en) 2009-11-25
US20070287737A1 (en) 2007-12-13
CN103121996B (zh) 2015-10-21
US8076486B2 (en) 2011-12-13
AR060807A1 (es) 2008-07-16
WO2007123936A1 (en) 2007-11-01
JP2009534386A (ja) 2009-09-24
CA2644425A1 (en) 2007-11-01
IL194546A0 (en) 2009-08-03
JP5525812B2 (ja) 2014-06-18
AU2007240860A1 (en) 2007-11-01
HK1127354A1 (en) 2009-09-25
EA200802050A1 (ru) 2009-04-28
KR20090005195A (ko) 2009-01-12
CN103121996A (zh) 2013-05-29
CN101426766A (zh) 2009-05-06
CN101426766B (zh) 2014-03-26

Similar Documents

Publication Publication Date Title
BRPI0711625A2 (pt) derivados de arilaminopiridina substituìda por heteroarila como inibidores de mek
ES2305317T3 (es) Derivados de amida bifenilcarboxilico como inhibidores de quinasa p38.
ES2566772T3 (es) Inhibidores de la quinasa c-fms
BRPI0611522A2 (pt) composto inibidor de enzima, seu uso, composição farmacêutica e método de inibição de atividade de uma enzima hdac
KR20060132882A (ko) 비스아릴우레아 유도체
US20110092505A1 (en) Organic compounds
ES2419007T3 (es) Ciertas entidades químicas, composiciones y procedimientos
BR112012017441B1 (pt) compostos e métodos
CA2791680A1 (en) Compounds and therapeutic uses thereof
BRPI1011043B1 (pt) fenilureias e fenilamidas substituídas como ligantes de receptor de vaniloide, seus usos e seu processo de preparação, e composição farmacêutica
SK168097A3 (en) N-heteroaryl-pyridinesulfonamide derivatives and their use as endothelin antagonists
AU2025202660A1 (en) Compounds
US20130317027A1 (en) Compounds and therapeutic uses thereof
KR20100130235A (ko) 이미노피리딘 유도체 및 이의 용도
BR112016028270B1 (pt) Composto derivado de 2-acilaminotiazol, composição farmacêutica que compreende dito composto e uso terapêutico do mesmo
BRPI0619260A2 (pt) derivados de oxadiazol com atividade de receptor ctrh2, composição farmacêutica que os compreende e uso dos referidos derivados
Rezaee Zavareh et al. Design, synthesis and biological evaluation of some oxadiazole derivatives as novel amide-based inhibitors of soluble epoxide hydrolase
WO2011009484A1 (en) Arylpyrazoles and arylisoxazoles and their use as pkd modulators
AU2005309760A1 (en) 2,3,4,6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of Alzheimer's disease
JP2009519208A (ja) アミド誘導体を含有する医薬組成物
TW201245187A (en) Pyrazole derivatives
WO2021127301A1 (en) 4-phenyl-n-(phenyl)thiazol-2-amine derivatives and related compounds as aryl hydrocarbon receptor (ahr) agonists for the treatment of e.g. angiogenesis implicated or inflammatory disorders
US8227492B2 (en) Sulfoxamine derivatives as factor Xa inhibitors
WO2013066834A1 (en) Compounds and methods
GB2640329A (en) Hedgehog acyltransferase inhibitors

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: MERCK SERONO S.A. (CH)

Free format text: NOME ALTERADO DE: LABORATOIRES SERONO SA

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 5A ANUIDADE.